Abstract
The goal of our study was to prepare carboplatin niosomes for enhanced delivery to cancer cells by thin film hydration technique using (cholesterol: surfactant) in the micromolar ratio of 30:100 and with/without the addition of charge inducing agents and Pluronic F 68. Photomicrographs of the formulations show the presence of multilamellar vesicles in the forumulation with Tween 80 and Pluronic F 68. The vesicle size of the formulation was found to be in the size range of 0.01-1µm. Carboplatin niosome formulation without any charge inducing agent and Pluronic F68 shows good drug entrapment (89.24%) with an in vitro release of 87.23% in 12 hours. Drug release kinetics of the formulation follows the Non Fickian diffusion mechanism and exhibits first order release kinetics. The in vitro cytotoxicity results of the formulations reveal that the Tween 80 formulation with Pluronic shows the highest level of cytotoxicity (90%) when compared with drug in solution. Also, the stability studies of the formulations reveal that the formulations were stable in refrigerated condition.
Keywords: Carboplatin, Cancer and Niosomes, in vitro Cytotoxicity, Drug targeting, therapeutic, immunoglobulins, serum proteins, synthetic polymers, liposomes, microspheres, erythrocytes, phospholipid, nonionic surfactant, viruses.
Drug Delivery Letters
Title:Formulation and Evaluation of in vitro Cytotoxicity of Carboplatin Niosomes
Volume: 2 Issue: 3
Author(s): V. Sankar, I. R. Antony Noby, B. Ramakrishna, Elizabeth Babu, Shalini Devi Penmetsa and Sivaram Hariharan
Affiliation:
Keywords: Carboplatin, Cancer and Niosomes, in vitro Cytotoxicity, Drug targeting, therapeutic, immunoglobulins, serum proteins, synthetic polymers, liposomes, microspheres, erythrocytes, phospholipid, nonionic surfactant, viruses.
Abstract: The goal of our study was to prepare carboplatin niosomes for enhanced delivery to cancer cells by thin film hydration technique using (cholesterol: surfactant) in the micromolar ratio of 30:100 and with/without the addition of charge inducing agents and Pluronic F 68. Photomicrographs of the formulations show the presence of multilamellar vesicles in the forumulation with Tween 80 and Pluronic F 68. The vesicle size of the formulation was found to be in the size range of 0.01-1µm. Carboplatin niosome formulation without any charge inducing agent and Pluronic F68 shows good drug entrapment (89.24%) with an in vitro release of 87.23% in 12 hours. Drug release kinetics of the formulation follows the Non Fickian diffusion mechanism and exhibits first order release kinetics. The in vitro cytotoxicity results of the formulations reveal that the Tween 80 formulation with Pluronic shows the highest level of cytotoxicity (90%) when compared with drug in solution. Also, the stability studies of the formulations reveal that the formulations were stable in refrigerated condition.
Export Options
About this article
Cite this article as:
Sankar V., R. Antony Noby I., Ramakrishna B., Babu Elizabeth, Devi Penmetsa Shalini and Hariharan Sivaram, Formulation and Evaluation of in vitro Cytotoxicity of Carboplatin Niosomes, Drug Delivery Letters 2012; 2 (3) . https://dx.doi.org/10.2174/2210304x11202030223
DOI https://dx.doi.org/10.2174/2210304x11202030223 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Editorial
International Journal of Sensors, Wireless Communications and Control Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
Current Gene Therapy Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Detection of VEGF165 Using an Aptamer Affinity Probe in Microchip Capillary Electrophoresis
Current Pharmaceutical Analysis Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Oxidative stress and myocarditis
Current Pharmaceutical Design Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Patent Selections
Recent Patents on Drug Delivery & Formulation A Preliminary Study of the Action of Virtosomes from Non-dividing Cells on Tumour Cell Replication in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly <i>via</i> Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling
MicroRNA Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Calcium and Zinc DTPA Administration for Internal Contamination with Plutonium-238 and Americium-241
Current Pharmaceutical Biotechnology